Skip to main content

Table 2 Cumulative proportions of treatment success (adequate clinical and parasitological response) for each treatment arm at fixed time points in pregnant women

From: A randomized controlled trial of dihydroartemisinin-piperaquine, artesunate-mefloquine and extended artemether-lumefantrine treatments for malaria in pregnancy on the Thailand-Myanmar border

  Cumulative percentage of treatment success (95% CI) estimated by Kaplan-Meier method p value
DP ASMQ AL+
P. falciparum* PCR-corrected N = 49 N = 55 N = 50 0.13
 Day 28 93.7% (81.6–97.9) 81.5% (68.4–89.6) 91.9% (79.8–96.9)  
 Day 42 93.7% (81.6–97.9) 81.5% (68.4–89.6) 87.5% (74.3–94.2)  
 Day 63 93.7% (81.6–97.9) 79.6% (66.1–88.1) 87.5% (74.3–94.2)  
 Delivery 93.7% (81.6–97.9) 79.6% (66.1–88.1) 87.5% (74.3–94.2)  
P. falciparum* PCR-uncorrected N = 49 N = 57 N = 50 0.07
 Day 28 93.7% (81.6–97.9) 80.4% (67.4–88.6) 91.9% (79.8–96.9)  
 Day 42 91.4% (78.7–96.7) 80.4% (67.4–88.6) 87.5% (74.3–94.2)  
 Day 63 91.4% (78.7–96.7) 78.5% (65.3–87.2) 87.5% (74.3–94.2)  
 Delivery 91.4% (78.7–96.7) 70.7% (53.8–82.4) 84.6% (70.2–92.4)  
P. vivax* N = 125 N = 117 N = 126 0.0006
 Day 28 100.0% 100.0% 95.8% (90.2–98.2)  
 Day 42 98.3% (93.4–99.6) 99.0% (93.2–99.9) 79.3% (70.8–85.6)  
 Day 63 82.9% (74.5–88.8) 89.5% (81.4–94.2) 68.5% (59.0–76.1)  
 Delivery 20.6% (5.1–43.4) 46.0% (30.9–60.0) 28.7% (10.0–50.8)  
Any malaria recurrence N = 171 N = 169 N = 170 0.03
 Day 28 98.2% (94.6–99.4) 92.5% (87.2–95.7) 93.9% (88.9–96.6)  
 Day 42 95.1% (90.4–97.5) 90.6% (84.8–94.2) 79.2% (72.0–84.7)  
 Day 63 83.1% (76.1–88.2) 80.8% (73.4–86.2) 69.9% (62.0–76.4)  
 Delivery 37.3% (18.7–56.0) 48.7% (37.3–59.2) 43.7% (26.5–59.7)  
  1. AL+ artemether-lumefantrine extended regimen, ASMQ artesunate-mefloquine, CI confidence interval, DP dihydroartemisinin-piperaquine, PCR polymerase chain reaction
  2. *Including co-infection of P. falciparum and P. vivax
  3. p values by log-rank test or Wilcoxon test (). For all endpoints, + 3 days allowed